Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06218706 · ClinicalTrials.gov registry record · NA
LIFU for Treatment for Refractory Opioid Use Disorder
A NA study of Opioid Use Disorder, sponsored by Ali Rezai.
- Recruiting
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT06218706: Recruiting NA study of Opioid Use Disorder, sponsored by Ali Rezai.
NCT06218706 is a NA study of Opioid Use Disorder that is actively recruiting participants, run by Ali Rezai. The registered enrollment target is 34 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06218706, a NA study of Opioid Use Disorder, is actively recruiting participants, sponsored by Ali Rezai.
- RECRUITING
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, sham-controlled, partial crossover study investigating LIFU targeting the NAc and VC for participants with severe, treatment refractory OUD.
Primary Outcome
Safety will be assessed by recording all adverse events that are treatment related. Each Adverse Event will be documented for patterns of occurrence.
Conditions Studied
Interventions
- DEVICE Low Intensity Focussed Ultrasound
Study Locations (1)
West Virginia
- WVU Rockefeller Neuroscience Institute - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2024-05-09 |
| Est. Completion | 2028-03-01 |
| Phase | NA |
What NCT06218706 shows while recruiting
NCT06218706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Low Intensity Focussed Ultrasound is the first listed.
NCT06218706 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT06218706 about?
NCT06218706 is a clinical study titled "LIFU for Treatment for Refractory Opioid Use Disorder". This is a randomized, double-blind, sham-controlled, partial crossover study investigating LIFU targeting the NAc and VC for participants with severe, treatment refractory OUD.
What is the current status of trial NCT06218706?
This trial is currently recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2024-05-09. Estimated completion is 2028-03-01.
What conditions does trial NCT06218706 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06218706?
The interventions under investigation include: Low Intensity Focussed Ultrasound (DEVICE).
Who is sponsoring clinical trial NCT06218706?
This trial is sponsored by Ali Rezai, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06218706 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06218706's enrollment target sits among peer trials
34 199th of 257 higher than 57 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
Using Facebook to Support Opioid Recovery Among American Indian Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI